AI Drug Discovery Predictive Oncology Leads PRISM NextGen Tech and AI Index on Ovarian Cancer Abstract Acceptance

Predictive Oncology Inc. (POAI) has announced that an abstract has been accepted for presentation at the 2024 American Society of Clinical Oncology Annual Meeting in Chicago. The meeting will take place from May 31st – June 4th. The study used multi-omic machine learning models to attempt to better predict short- and long-term survival outcomes in females with high grade sesrous ovarian cancer (HGSC) compared to clinical data alone. This study was in collaboration with UPMC Magee-Womens Hospital in Pittsburgh, PA.

The company participates in the PRISM NextGen Tech and AI Index and is currently up ~26%.

Share This Article

 

About the Author

AI Drug Discovery Predictive Oncology Leads PRISM NextGen Tech and AI Index on Ovarian Cancer Abstract Acceptance

Ashlee Vogenthaler

Markets Editor